Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05262907 · ClinicalTrials.gov registry record · NA
Ventripoint Single Ventricle Study
A NA study of Congenital Heart Disease and Single-ventricle, sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05262907: Recruiting NA study of Congenital Heart Disease and Single-ventricle, sponsored by Duke University.
NCT05262907 is a NA study of Congenital Heart Disease and Single-ventricle that is actively recruiting participants, run by Duke University. The registered enrollment target is 100 participants, below the 472-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05262907, a NA study of Congenital Heart Disease and Single-ventricle, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will validate a coordinate-based 3-dimensional echocardiographic technique for the assessment of cardiac size and function in children and young adults with functional single ventricles.
Primary Outcome
Ejection Fraction (EF) is a measurement of the percentage of blood leaving your heart each time it squeezes (contracts)with each heart beat.
Conditions Studied
Interventions
- DEVICE Transthoracic Echocardiogram or Cardiac MRI
- DEVICE Ventripoint Echocardiogram
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-07-08 |
| Est. Completion | 2027-08 |
| Phase | NA |
What NCT05262907 shows while recruiting
NCT05262907 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 472-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Congenital Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Transthoracic Echocardiogram or Cardiac MRI is the first listed.
NCT05262907 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05262907 about?
NCT05262907 is a clinical study titled "Ventripoint Single Ventricle Study". This study will validate a coordinate-based 3-dimensional echocardiographic technique for the assessment of cardiac size and function in children and young adults with functional single ventricles.
What is the current status of trial NCT05262907?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-07-08. Estimated completion is 2027-08.
What conditions does trial NCT05262907 study?
This clinical trial studies the following conditions: Congenital Heart Disease, Single-ventricle.
What interventions are being tested in trial NCT05262907?
The interventions under investigation include: Transthoracic Echocardiogram or Cardiac MRI (DEVICE), Ventripoint Echocardiogram (DEVICE).
Who is sponsoring clinical trial NCT05262907?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05262907 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05262907's enrollment target sits among peer trials
100 29th of 63 higher than 33 of 63 other Congenital Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fontan Fitness Trial
RECRUITING · NA
-
Blood Conservation in Patients (3.5-12kg) Undergoing Congenital Cardiac Surgery
RECRUITING · NA
-
The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study
RECRUITING · NA
-
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
RECRUITING · NA
-
A Study of Hemodynamic Cardiopulmonary Exercise for CHD
RECRUITING · NA
-
Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI